Medline, Inc. successfully completed a $7.2 billion initial public offering, aiming to reduce debt and strengthen its market position in the healthcare sector.
Information on the Target
Medline, Inc. is a prominent provider of medical-surgical products and supply chain solutions, catering to various healthcare settings. Headquartered in Northfield, Illinois, the company employs over 43,000 individuals and operates in more than 100 countries, positioning itself as a leader in the healthcare industry. Medline's extensive product portfolio, strong supply chain, and innovative clinical solutions enable healthcare providers to enhance their clinical, financial, and operational outcomes.
The recent upsized initial public offering (IPO) consisted of 248,439,654 shares of Class A common stock, priced at $29.00 per share, resulting in gross proceeds of approximately $7.2 billion. The proceeds will primarily be utilized to reduce existing debt and facilitate the redemption of equity interests held by pre-IPO stakeholders.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The healthcare sector in North America has seen significant growth driven by continuous advancements in medical technology and an increase in healthcare spending. The demand for medical supplies and equipment is anticipated to r
Similar Deals
Blackstone, TPG, and other minorities (ADIA, GIC) → Hologic, Inc.
2025
Single Institutional Investor → Glucotrack, Inc.
2025
Novartis → Regulus Therapeutics
2025
Crescent Biopharma, Inc. → GlycoMimetics, Inc.
2025
MapLight Therapeutics → MapLight Therapeutics
2025
Abbott Laboratories → Senseonics Holdings, Inc.
2025
Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LP
invested in
Medline, Inc.
in 2025
in a Public-to-Private (P2P) deal
Disclosed details
Transaction Size: $7,200M